GLP Watchdog

GoodRx vs MEDVi

MEDVi has an open FDA warning letter dated February 20, 2026. GoodRx has none. No price lines up like for like: GoodRx and MEDVi publish prices for different products.

To see where both sit among the other sellers, read our best weight-loss injection providers board.

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed

The record

GoodRx / MEDVi

GoodRx logo

GoodRx

7.8/10

MEDVi logo

MEDVi

7.7/10

FDA warning letters
None on record
Pharmacy
Brand-name only; no compounding
Lowest standing price
$149/moFoundayo (orforglipron) pill
$199/moCompounded semaglutide injection
States
48 states
All 50 states
Checked
Prices captured Record checked October 2026
Prices captured Record checked October 2026
Visit GoodRx
Visit MEDVi

Neither GoodRx nor MEDVi pays us. Links to them earn nothing. Scores: GoodRx 7.8, MEDVi 7.7. How we are paid

What the record shows

  1. 01

    MEDVi has an open FDA warning letter dated February 20, 2026. GoodRx has none.

  2. 02

    MEDVi names three pharmacies, all 503A. GoodRx sells brand-name medication only.

  3. 03

    No price lines up like for like: GoodRx and MEDVi publish prices for different products.

  4. 04

    Only GoodRx lists a price for brand-name tirzepatide pen and Foundayo (orforglipron) pill. Only MEDVi lists a price for compounded semaglutide injection.

  5. 05

    MEDVi covers two states GoodRx does not.

Prices and terms, product by product

A price is set against the other side only for the same product, and only when both are standing monthly or 4-week rates. Those pairs are compared by yearly cost.

GoodRx

MEDVi

Compounded semaglutide injection
Not sold or not priced

$199/mo

$2,388 a year

Brand-name tirzepatide pen

$299/mo

$3,588 a year

Not sold or not priced
Foundayo (orforglipron) pill

$149/mo

$1,788 a year

Not sold or not priced
Price includes
Not stated
Medication, clinician visits, shipping, coaching
Cancel any time
Yes, stated
Yes, stated
Minimum term
None
None; billed monthly
Refunds
Services and medication are generally non-refundable
Full refund if medically disqualified, or if canceled within 72 hours before any service; none for months already billed
Early-exit fee
Not stated
None stated

Read off each seller’s own pages. GoodRx: October 30, 2026. MEDVi: October 25, 2026. Every plan and dose we hold is on the full review.

The case for each

The case for GoodRx

7.8/10
  • No FDA warning letter on record
  • Sells brand-name tirzepatide pen and Foundayo (orforglipron) pill, which MEDVi does not price
Visit GoodRx

The case for MEDVi

7.7/10
  • Sells compounded semaglutide injection, which GoodRx does not price
  • Open FDA warning letter, February 20, 2026
Visit MEDVi

Scores

GoodRx 7.8 · MEDVi 7.7 out of 10. Six weighted parts.

Value25%

8.7A
vs
B
5.0

Effectiveness25%

10.0A
vs
B
10.0

User Experience15%

5.0A
vs
B
8.0

Trust & Safety15%

6.0A
vs
B
6.0

Accessibility10%

9.7A
vs
B
10.0

Support10%

5.0A
vs
B
8.5

The score is the same formula for every seller. Payment does not enter it. Method

GoodRx vs MEDVi: questions

MEDVi has an open FDA warning letter dated February 20, 2026. GoodRx has none. Letters are matched to a seller by company, domain and address, never by a similar name.
MEDVi names three pharmacies, all 503A. GoodRx sells brand-name medication only. A 503A pharmacy compounds for named patients on a prescription; a 503B outsourcing facility is registered with FDA and inspected under federal manufacturing rules.
No price lines up like for like: GoodRx and MEDVi publish prices for different products. We only set two prices against each other when they are for the same product and both are standing month-to-month or 4-week rates.
GoodRx states you can cancel at any time; refunds: services and medication are generally non-refundable. MEDVi states you can cancel at any time; refunds: full refund if medically disqualified, or if canceled within 72 hours before any service; none for months already billed.
Neither GoodRx nor MEDVi pays us. Links to them earn nothing. Scores: GoodRx 7.8, MEDVi 7.7.

Other sellers we are paid by

Affiliate partners outside this pair. Each has its own record and review, scored the same way.

Sellers closest to these two

Matched on molecule, form and price. Every pair we list · The register

Brand names on this page are registered marks. Novo Nordisk holds Wegovy®, Ozempic® and Rybelsus®; Eli Lilly holds Zepbound®, Mounjaro® and Foundayo®. Neither company has any tie to GLP Watchdog. Trademarks